Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3955586 | 0.83 | DAGLA (0.60) | DAGLAMAPTLMNAXDHFAAH | |
| SCHEMBL5522120 | 0.82 | DAGLA (0.62) | DAGLAXDHFAAHCES1 | |
| SCHEMBL4049877 | 0.79 | DAGLA (0.62) | DAGLAMAPTLMNAXDHFAAH | |
| SCHEMBL4048199 | 0.79 | DAGLA (0.60) | DAGLAXDHFAAHCES1 | |
| SCHEMBL4048936 | 0.79 | DAGLA (0.44) | DAGLAMAPTXDHFAAHCES1 | |
| SCHEMBL2701430 | 0.76 | MAPT (0.57) | MAPTMAPK1LMNACYP1A2THRB | |
| SCHEMBL4046625 | 0.75 | DAGLA (0.62) | DAGLAFAAHCES1 | |
| SCHEMBL5095572 | 0.75 | MEN1 (0.51) | MAPTMAPK1LMNACYP1A2THRB | |
| SCHEMBL4050534 | 0.75 | DAGLA (0.55) | DAGLAMAPTLMNAXDHFAAH | |
| SCHEMBL27654631 | 0.74 | MAPT (0.58) | MAPTMAPK1LMNACYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | claimed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | claimed |
| EP-1744755-B1 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2012-12-05 | — | — | EP | disclosed |
| EP-1744755-A4 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2009-07-15 | — | — | EP | disclosed |
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | IRM LLC (BM) | 2007-10-04 | — | — | US | disclosed |
| EP-1744755-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM, LLC (BM) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005107464-A2 | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S INHIBITORS | IRM LLC (BM) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232606-A1 | Compounds and Compositions as Cathepsin S Inhibitors | CTSS, CTSB, CTSF | DAGLA 2256/4885MAPT 1035/4885MAPK1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.